Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in Series A financing.
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences
Sponsored · Video
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace
